ShanX Medtech, an Eindhoven-based MedTech company developing next-generation diagnostics for antimicrobial susceptibility testing, has secured €24 million in Seed financing to move its technology toward market launch.
The funding will be used to expand operations, complete clinical validation, and progress regulatory approvals ahead of commercial rollout.
Funding structure and investors
The oversubscribed round combines equity, grants, and public financing instruments. Equity participation was led by Borski Fund, alongside NextGen Ventures, CbusineZ, Brabantse Ontwikkelings Maatschappij, Invest-NL, and a strategic angel fund.
In parallel, ShanX Medtech was awarded an €8.85 million contract from the European Commission under programme HADEA/2025/CPN/0006. The contract was developed by the Health Emergency Preparedness and Response Authority in cooperation with the European Health and Digital Executive Agency, bringing the company’s total financing package to €24 million.
Advertisement
Addressing delays in antibiotic treatment
ShanX Medtech was founded in 2019 following a clinical case that highlighted the risks of delayed diagnostic results in infectious disease treatment. Current antimicrobial susceptibility testing often takes days, during which clinicians must prescribe broad-spectrum antibiotics without precise resistance data.
According to founder and CEO Dr Sophia E. Shanko, the company’s goal is to give clinicians actionable diagnostic evidence while treatment decisions still matter. The new funding accelerates the delivery of ultra-rapid testing to both laboratory and point-of-care settings, with a focus on speed, simplicity, and accessibility.
Technology and clinical focus
Based at Eindhoven’s High Tech Campus, ShanX Medtech develops in-vitro diagnostic solutions that determine antibiotic susceptibility directly from patient samples. Its platform uses proprietary chemistry to monitor microbial metabolism in real time, delivering results in under one hour with minimal manual handling.
At the core of the system is the company’s FLORA™ chemical composition, which enables continuous observation of pathogen response to antibiotics. This approach significantly shortens turnaround times compared to conventional AST methods that require specialised staff and extended incubation.
Initial go-to-market efforts are centred on women’s health applications, particularly urinary tract infections, with longer-term expansion planned across additional infectious disease indications.
Path to market
The newly secured capital will be directed toward final product development, multi-site clinical studies, regulatory submissions, and preparation for commercial launch.
From an investor perspective, ShanX Medtech’s platform stands out for both its technical differentiation and scalability. Borski Fund notes that while the initial clinical focus is narrow and well defined, the underlying technology has broad applicability across antimicrobial resistance diagnostics.
With antimicrobial resistance recognised as a growing global health threat, ShanX Medtech positions itself to shorten the gap between diagnosis and treatment, enabling more precise antibiotic use at a time when speed and accuracy are increasingly critical.
